棕榈酸帕利哌酮(Paliperidone Palmitate) - 药物靶点：5-HT receptor x D2 receptor_在研适应症：分裂情感性障碍，精神分裂症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Paliperidone palmitate (JAN/USAN)、Xeplion Aqueous Suspension、paliperidone

+ [17]

靶点

5-HT receptor x D2 receptor

作用机制

5-HT receptor拮抗剂(5-羟色胺受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

其他疾病

在研适应症

分裂情感性障碍精神分裂症

非在研适应症

中枢神经系统疾病神经认知障碍

原研机构

Janssen Global Services LLC

在研机构

Janssen Pharmaceuticals, Inc.Janssen Pharmaceutical KKJanssen-Cilag International NV

+ [4]

非在研机构

Janssen Scientific Affairs LLC

Janssen Pharmaceutica NVJanssen Research & Development LLC

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (2009-07-31),

精神分裂症

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)

登录后查看时间轴

结构

分子式C39H57FN4O4

InChIKeyVOMKSBFLAZZBOW-UHFFFAOYSA-N

CAS号199739-10-1

关联

88

项与棕榈酸帕利哌酮相关的临床试验

CTRI/2024/02/062550 / RecruitingN/A

A Randomized, Open Label, Multicenter, Multiple Dose, Two Treatment, Two Period, Two Way, Crossover, Steady State Bioequivalence Study Between Paliperidone Palmitate Extended Release Intramuscular Injectable Suspension 156 mg per mL of Eugia Pharma Specialities Limited, India and INVEGA SUSTENNA Paliperidone Palmitate Extended Release Intramuscular Injectable Suspension 156 mg per mL Manufactured for Janssen Pharmaceuticals, Inc Titusville, NJ 08560, USA in Adult Patients with Schizophrenia or Schizoaffective Disorder. - NIL

开始日期2024-02-20

申办/合作机构

Eugia Pharma Specialities Ltd.

[+1]

CTR20233704 / RecruitingN/A

棕榈酸帕利哌酮注射液（1M）在中国精神分裂症患者中进行的多中心、随机、开放、平行设计、多次给药生物等效性临床试验

评价石药集团中诺药业（石家庄）有限公司生产的棕榈酸帕利哌酮注射液（受试制剂）与 Janssen Pharmaceutica N.V.生产的棕榈酸帕利哌酮注射液（参比制剂，商品名：善思达®）多次给药在稳态下的生物等效性.

开始日期2023-12-18

申办/合作机构

石药集团中诺药业（石家庄）有限公司

CTR20233833 / RecruitingN/A

精神分裂症患者接受棕榈酸帕利哌酮注射液多次给药的随机、开放、双交叉、双周期、稳态人体生物等效性试验

主要研究目的：评价精神分裂症患者多次肌肉注射受试制剂丽珠集团丽珠制药厂研制的棕榈酸帕利哌酮注射液（代号：LZ1069）和参比制剂原研厂家 Janssen Pharmaceutica N.V.研制的棕榈酸帕利哌酮注射液（商品名：善思达®）达稳态后两者的生物等效性。次要研究目的：评价受试制剂和参比制剂在中国精神分裂症患者中多次肌肉注射的安全性和耐受性。

开始日期2023-12-11

申办/合作机构

丽珠集团丽珠制药厂

100 项与棕榈酸帕利哌酮相关的临床结果

登录后查看更多信息

100 项与棕榈酸帕利哌酮相关的转化医学

登录后查看更多信息

100 项与棕榈酸帕利哌酮相关的专利（医药）

登录后查看更多信息

569

项与棕榈酸帕利哌酮相关的文献（医药）

2024-11-30·Clinical Psychopharmacology and Neuroscience

The Real-world Effect of Long-acting Injectable Antipsychotics on Annual Medical Costs of Korean Schizophrenia Patients

Article

作者: Chi, SuHyuk ; Ko, Jeong Kyung ; Han, Changsu ; Lee, Moon-Soo ; Jeong, Hyung-Ghang

ObjectiveSchizophrenia is a severe and chronic mental disorder that significantly impacts cognitive, social, and occupational functions, leading to substantial economic burdens. Long-acting injectable (LAI) antipsychotics have been introduced to improve treatment adherence and outcomes, yet their economic impact remains debated. We aim to analyze the impact of LAIs on the medical costs of Korean schizophrenia patients.MethodsA retrospective analysis of 164 schizophrenia patients treated with LAI antipsychotics, paliperidone palmitate, and aripiprazole monohydrate at Korea University Guro Hospital between January 2017 and July 2022 was performed. Comparisons of inpatient department (IPD) and outpatient department (OPD) healthcare expenditures one year before and after LAI initiation were conducted.ResultsLAIs led to an increase in annual OPD costs (1,437.44 ± 1,127.60 to 4,015.42 ± 1,204.59; units: 1,000 KRW) but significantly reduced IPD admission associated costs (3,826.06 ± 5,500.63 to 698.06 ± 3,619.38; units: 1,000 KRW). After LAI administration, there was an overall reduction in total annual healthcare costs (5,263.49 ± 5,333.11 to 4,713.48 ± 3,625.89; units: 1,000 KRW), but it was not statistically significant.ConclusionAlthough the use of LAIs did not significantly lower the first-year medical costs of schizophrenia patients, they offer beneficial economic impacts over time by reducing hospitalization-associated costs. Future research should focus on long-term cost analyses and the impacts of newer LAI formulations.

2024-09-01·Journal of Addiction Medicine

The Pharmacological Management of Ketamine Use Disorder: A Systematic Review

Review

作者: Sanderson, Elizabeth ; Roberts, Emmert ; Guerrini, Irene

ObjectivesThere has been limited evidence synthesis examining treatment of ketamine use disorder. We aimed to conduct a systematic review to assess the efficacy and tolerability of pharmacological interventions in the management of ketamine use disorder.MethodsWe searched MEDLINE, EMBASE, PsychINFO, and CENTRAL (Cochrane Central Register of Controlled Trials) from database inception to November 14, 2023, for studies of any design that reported on any pharmacological intervention in the management of ketamine use disorder. We extracted any reported measure of efficacy or tolerability and assessed outcome quality using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework. We planned to combine outcomes using random-effects meta-analysis, where this was not possible results were reported narratively.ResultsTwelve studies met the inclusion criteria reporting on 368 participants. These comprised 1 controlled trial, 2 retrospective case series, and 9 case reports. Two studies reported on ketamine intoxication, 6 on withdrawal, and 4 on craving/relapse prevention. All studies reported only descriptive outcomes, and all evidence was of very low quality. Benzodiazepine regimens and haloperidol were reported to have potential utility in intoxication and withdrawal, whereas naltrexone, lamotrigine, and a combination of paliperidone palmitate and bupropion were reported to have potential utility in craving/relapse prevention.ConclusionsThere is a paucity of research into pharmacological management of ketamine use disorder. The limited very low-quality evidence suggests benzodiazepine regimens may be most salient for future exploration in management of ketamine intoxication and withdrawal, whereas case reports suggest naltrexone, lamotrigine, and paliperidone palmitate plus bupropion may potentially merit further investigation with regard to craving/relapse prevention.

2024-09-01·Journal of Managed Care & Specialty Pharmacy

Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder

Article

作者: Lee, Inyoung ; Patel, Charmi ; Wang, Yi ; Benson, Carmela ; Shaikh, Nazneen Fatima ; Zhao, Xiaohui ; Near, Aimee M.

BACKGROUNDOnce-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic approved for the treatment of schizophrenia and schizoaffective disorder (SCA) in adults.OBJECTIVETo assess treatment patterns and schizophrenia/SCA-related hospitalization following payer rejection, patient reversal, or payment of an initial PP1M claim.METHODSThis was a retrospective cohort study using the IQVIA Formulary Impact Analyzer database linked to the Medical Claims, Hospital Charge Detail Master, and Experian consumer databases. Patients with schizophrenia/SCA and ≥1 PP1M pharmacy claim from January 1, 2018, to February 28, 2022, were identified and stratified into 3 cohorts based on the transaction status of the initial PP1M claim (index date): rejected (payer not approved), reversed (payer approved, patient abandoned), and paid (payer approved, patient filled). Patient characteristics during the 12 months before the index date, subsequent treatment patterns, and schizophrenia/SCA-related hospitalization for patients with >6 months of follow-up were assessed by cohort.RESULTSThe rejected, reversed, and paid cohorts included 1,260, 1,046, and 1,686 patients, respectively. Across these cohorts, the mean ages ranged between 39.2 and 44.5 years; more than half were male (50.8%-51.6%) and White (50.6%-58.3%); 19.8%-24.6% of patients had a Quan-Charlson Comorbidity Index score of ≥2. Rates of prior atypical oral and long-acting injectable antipsychotic use ranged between 76.4%-80.3% and 7.8%-12.7%, respectively. Among patients with ≥6 months of follow-up, 52.2% in the rejected and 53.1% in the reversed cohorts had a subsequent paid PP1M claim during the study period; the median (quartile 1-quartile 3) time to the first paid PP1M claim was 22 (5-74) days for rejection and 11 (1-41) days for reversal. In the rejected and reversed cohorts, 10.2% (n = 111) and 9.8% (n = 90) of patients, respectively, did not receive any paid claim for an antipsychotic after the initial PP1M rejection/reversal. The prevalence of schizophrenia/SCA-related hospitalization during follow-up was similar between patients with a paid (7.4%) and rejected PP1M claim (7.0%; P = 0.689) but higher among patients with a reversed claim (10.8%; P = 0.004). After adjusting for confounders, patients in the reversed cohort were 39% more likely to have a schizophrenia/SCA-related hospitalization than those in the paid cohort (odds ratio = 1.39; 95% CI = 1.03-1.87).CONCLUSIONSPayer rejection and patient reversal of initial PP1M claims is a form of primary nonadherence and may influence patient trajectory. Data from this study suggest that patient reversal of PP1M may lead to an increased risk of schizophrenia/SCA-related hospitalizations, potentially caused by missed or delayed treatment. Policy initiatives that remove barriers to primary adherence or fulfillment may help improve patients' clinical outcomes.

164

项与棕榈酸帕利哌酮相关的新闻（医药）

2024-11-11

·绿叶制药

绿叶制药靶向NET/DAT/GABAAR的抗抑郁1类创新药获准开展临床试验

绿叶制药集团宣布，1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验，拟用于治疗抑郁症。 LY03021为去甲肾上腺素转运体（NET）/多巴胺转运体（DAT）抑制剂、γ-氨基丁酸A受体正向变构调节剂（GABAAR PAM）。该产品基于绿叶制药新分子实体/新治疗实体技术平台（NCE/NTE）自主开发，是全新的三靶点作用机制抗抑郁药物，具有同类首创（First-in-Class）的潜质。目前尚未检索到相同机制的产品在研。抑郁症是各种原因引起的以显著和持久的抑郁症状群为主要临床特征并损害社会功能的一类心境障碍。流行病学数据显示：我国抑郁症患病人数呈上升趋势，抑郁症的终生患病率为3.4%、12个月患病率为2.1%1。抑郁症伴随高复发率、高自杀率、高致残率，严重影响家庭和社会。现有抗抑郁药总体有效率和治愈率低，且普遍存在起效较慢、残留症状多、复发风险高、不良反应多等局限。因此，如何快速有效的控制抑郁症的临床症状，进一步改善治疗效果和预后成为当下抗抑郁药物研发中需要攻克的难题。 LY03021同时针对NET、DAT和GABAAR三个靶点发挥作用。该产品通过作用于突触内GABAA受体亚型α1β2γ2和突触外GABAA受体亚型α4β3δ，增强GABA对GABAA受体激活，调节脑内谷氨酸-GABA能平衡，抑制下丘脑-垂体-肾上腺（HPA）轴过度激活，快速发挥抗抑郁作用。同时，LY03021通过抑制NET和DAT，增加脑内去甲肾上腺素（NE）和多巴胺（DA）水平，可显著改善抑郁症患者的核心症状、快感缺失和性功能障碍，并通过NE和DA的“唤醒机制”，消除因GABA受体激活引起的镇静、嗜睡和意识丧失等不良反应。非临床研究显示，LY03021给药后24小时即显著改善模型动物抑郁症状，且连续用药，药效可维持至为期21天的研究结束时，展现出兼具快速起效和长期连续用药保持疗效的优势。同时，该产品具有良好的安全性，NOAEL（未观察到毒副作用剂量）超出有效剂量50倍以上。绿叶制药集团创新研究院常务副院长田京伟博士表示：“抑郁症的发病机制复杂，涉及大脑中多种神经递质的相互作用。基于脑神经环路的多靶点调节是开发新型抗抑郁药物的一大突破口。NET、DAT和GABAAR三个靶点的协同，可快速发挥抗抑郁作用，并有望提升疗效，减少不良反应，以更好的满足临床需求。绿叶制药深耕CNS治疗领域十余年，已成功开发并上市多款创新产品组合。同时，我们持续洞察患者所需，结合CNS治疗领域的基础研究积累和研发技术优势，积极探索和布局全新作用机制的下一代创新药，为提升大众健康水平而努力。” 包括抑郁症在内的CNS治疗领域患者需求庞大，但新药研发进展相对较缓。绿叶制药拥有一系列具有国际竞争力的创新药和创新制剂，成为该治疗领域的领军力量。围绕CNS领域，绿叶制药的产品组合包括：在美获批上市的Erzofri®（棕榈酸帕利哌酮缓释混悬注射液）、Rykindo®（利培酮缓释微球注射剂），在中国上市的若欣林®（盐酸托鲁地文拉法辛缓释片）、金悠平®（注射用罗替高汀微球）等。此外，公司另有包括TAAR1/ 5-HT2CR双靶点激动剂（LY03020）、VMAT2/Sigma1双靶点新药（LY03015）等多个1类创新药处于临床阶段。绿叶制药集团是致力于创新药物的研发、生产和销售的国际化制药公司。绿叶制药在中国、美国和欧洲设有研发中心，拥有超过30个中国在研药物和10多个海外在研药物。绿叶制药在微球、脂质体、透皮释药等先进药物递送技术领域达到国际先进水平，在新分子实体、生物抗体领域收获多项创新成果，并在细胞治疗、基因治疗等领域进行了积极布局和开发。绿叶制药深度布局全球供应链体系，已在全球建有8大生产基地并建立了与国际接轨的GMP质量管理和控制体系。公司现有30余个上市产品，产品覆盖肿瘤、中枢神经系统、心血管、消化与代谢等治疗领域；业务遍及全球80多个国家和地区，其中包括中国、美国、欧洲、日本等全球主要医药市场，以及高速增长的各地新兴市场。参考文献： 1.Yueqin Huang, Yu Wang, Hong Wang, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry.2019 Mar;6(3):211-224. 内容来源于网络，如有侵权，请联系删除。

申请上市

2024-11-11

·Pharma CMC

绿叶制药：抗抑郁1类新药获批临床

今日（11月11日），绿叶制药发布公告，集团的1类创新药LY03021已获得国家药监局药品审评中心批准开展临床试验，拟用于治疗抑郁症。 Y03021为去甲肾上腺素转运体（NET）/多巴胺转运体（DAT）抑制剂、g－氨基丁酸A受体正向变构调节剂（GABAARPAM），是全新的三靶点作用机制抗抑郁药物，具有同类首创(First-in-Class)的潜质。据公告披露，目前尚未检索到相同机制的产品在研。 LY03021同时针对NET、DAT和GABAAR三个靶点发挥作用。该产品通过作用于突触内GABAA受体亚型a1b2g2和突触外GABAA受体亚型a4b3d，增强GABA对GABAA受体的激活，调节脑内谷氨酸－GABA能平衡，抑制下丘脑－垂体－肾上腺（HPA）轴的过度激活，快速发挥抗抑郁作用。同时，LY03021通过抑制NET和DAT，增加脑内去甲肾上腺素（NE）和多巴胺（DA）水平，可显着改善抑郁症患者的核心症状、快感缺失和性功能障碍，并通过NE和DA的「唤醒机制」，消除因GABA受体激活引起的镇静、嗜睡和意识丧失等不良反应。非临床研究显示，LY03021给药后24小时即显着改善模型动物抑郁症状，且连续用药，药效可维持至为期21天的研究结束时，展现出兼具快速起效和长期连续用药保持疗效的优势。同时，该产品具有良好的安全性，NOAEL（未观察到毒副作用剂量）超出有效剂量50倍以上。包括抑郁症在内的CNS治疗领域患者需求庞大，但新药研发进展相对较缓。绿叶制药围绕CNS领域，产品组合包括：在美国获批上市的Erzofri®（棕榈酸帕利呱酮缓释混悬注射液）、Rykindo（利培酮缓释微球注射剂）®，在中国上市的若欣林®（盐酸托鲁地文拉法辛缓释片）、金悠平®（注射用罗替高汀微球）等。此外，绿叶制药另有包括TAAR1/5-HT2CR双靶点激动剂(LY03020)、VMAT2/Sigma1双靶点新药(LY03015)等多个1类创新药处于临床阶段。

申请上市上市批准

2024-11-08

·强生中国

“强势”加码！聚力开创健康新篇章

第七届中国国际进口博览会正如火如荼强生展台依然“新”光耀眼来！小编带你密切追踪强生进博大秀现场实况全放送！在进博会开展首日，强生隆重举行了“重磅新品发布会”，深度聚焦改写癌症历史、攻克心脑血管疾病、构筑健康老龄化和突破医疗科技边界四大核心健康议题，13款首发、首秀产品悉数亮相。此外，11月6日，强生创新制药在题为“科学领拓医药未来”新品上市新闻发布会上，宣布泰立珂®与善久达®两款重磅产品在华上市，为进博会“溢出效应”再添光彩。创新力十足的我们，在短短几天内更有 30余场重量级战略合作签约仪式在展台上火热进行共同蓄势加码创新，合力推动行业发展让创新成果惠及更多百姓！精彩纷呈，不止如此！强生凭借非凡创新实力成为媒体瞩目焦点，热度持续攀升跟上我们，一同见证热力时刻！ CCTV 进博观察：生命健康，如何更好守护？ ↑扫码查看↑ 人民日报进博看点｜“全勤生”强生携百余款创新产品如期赴约 ↑扫码查看↑ 新华社第七届进博会 | 中外企业高管为中国经济投下“信心票” ↑扫码查看↑ 新华社进博会医疗器械及医药保健展区前瞻从“首秀”“首展”看医疗领域前沿“黑科技” ↑扫码查看↑ 中国新闻网七赴进博，强生的“全勤生”故事 ↑扫码查看↑ 经济日报以进博为桥，跨国企业共享进博会“中国机遇” ↑扫码查看↑ 环球时报共赴进博之约，各国企业共享中国发展新机遇 ↑扫码查看↑ Shine Executives encouraged by Premier Li Qiang's CIIE speech ↑扫码查看↑ 文汇报一口气带来百余款创新产品，强生多款重磅新品发布 ↑扫码查看↑ 人民日报健康客户端第七届进博会进行中！强生作为进博会的“元老级”参展企业，连续七届亮相，带来百余款创新产品 ↑扫码查看↑ 人民网善久达® (棕榈帕利哌酮酯注射液 (6M))在华上市 ↑扫码查看↑ 新华网全球首个多发性骨髓瘤BCMA×CD3双抗药物泰立珂®在中国上市，击破复发或难治性多发性骨髓瘤患者治疗困局 ↑扫码查看↑ 器械之家进博“医”览无余，强生医疗科技全线外科解决方案够硬核 ↑扫码查看↑ E药经理人硬核“黑科技”！强生携创新心脑血管解决方案亮相进博 ↑扫码查看↑ MedTrend医趋势 ↑点击查看↑ Abiomed在本届进博会带来的这款“中国首秀”产品，或将成为挽救和治疗他们的希望一同携手，书写合作新篇创新引领，共绘健康未来 *所有媒体报道版权归媒体所有

100 项与棕榈酸帕利哌酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05340	棕榈酸帕利哌酮	N05AX13	DB01267

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
分裂情感性障碍	美国	Janssen Pharmaceuticals, Inc.	2014-11-12
精神分裂症	美国	Janssen Pharmaceuticals, Inc.	2009-07-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
精神分裂症	申请上市	中国	山东绿叶制药有限公司	2024-07-27
分裂情感性障碍	临床2期	马来西亚	Janssen Scientific Affairs LLC	2010-09-01
分裂情感性障碍	临床前	印度	Janssen Scientific Affairs LLC	2010-09-01
分裂情感性障碍	临床前	罗马尼亚	Janssen Scientific Affairs LLC	2010-09-01
精神障碍	药物发现	墨西哥	Janssen Scientific Affairs LLC	2015-07-08
精神障碍	药物发现	巴西	Janssen Scientific Affairs LLC	2015-07-08
分裂情感性障碍	药物发现	保加利亚	Janssen Scientific Affairs LLC	2010-09-01
分裂情感性障碍	药物发现	乌克兰	Janssen Scientific Affairs LLC	2010-09-01
分裂情感性障碍	药物发现	菲律宾	Janssen Scientific Affairs LLC	2010-09-01
分裂情感性障碍	药物发现	南非	Janssen Scientific Affairs LLC	2010-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04072575 (CTgov)	临床3期	精神分裂症	178	Paliperidone Palmitate	醖製構壓觸觸積遞夢遞(積廠遞鏇鏇醖襯鏇簾觸) = 餘鏇廠積淵憲艱憲夢遞築糧醖鬱衊淵齋壓遞製 (齋憲壓蓋鹹鬱衊窪膚醖, 窪憲廠觸觸襯觸鏇鹽願 ~ 選壓膚遞積襯醖襯範積) 更多	-	2023-05-31
NCT04922593 (Corporate Publications) 人工标引	N/A	分裂情感性障碍 \| 精神分裂症	281	LY03010	(簾範鹽鹹製鹽壓積淵願) = LY03010 has an optimized initial dosed regimen and is bioequivalent when stable state is reached with multiple doses compared to the initial dosed regimen of INVEGA SUSTENNA® 鏇餘襯膚選網蓋醖獵構 (鹽獵簾齋淵製願鏇顧選 ) 更多	积极	2022-11-21
				INVEGA SUSTENNA
NCT02713282 (REMISSIO, Pubmed) 人工标引	临床3期	精神分裂症	303	paliperidone palmitate (overall population)	膚憲淵夢鏇觸襯網繭壓(廠齋蓋範製襯餘積膚鹹) = 膚簾積網艱蓋餘觸鹹選選鹹願齋構鹽積蓋築艱 (憲衊醖糧餘築醖艱糧獵 ) 更多	积极	2022-08-31
				paliperidone palmitate (Asian patients)	膚憲淵夢鏇觸襯網繭壓(廠齋蓋範製襯餘積膚鹹) = 積鬱繭獵鏇衊鹹築範網選鹹願齋構鹽積蓋築艱 (憲衊醖糧餘築醖艱糧獵 ) 更多
NCT03345342 (CTgov)	临床3期	精神分裂症	841	PP3M (DB PP3M)	蓋觸鑰醖蓋淵憲壓醖糧(積構網襯衊襯鏇遞製鏇) = 簾糧廠衊夢糧夢淵鑰淵願選蓋鹹選構壓鹽糧鏇 (築襯夢構蓋壓願襯積鏇, 淵構網膚願遞鹽廠鹹顧 ~ 糧艱鑰繭壓膚糧蓋夢壓) 更多	-	2021-12-09
				placebo+PP6M (DB PP6M)	蓋觸鑰醖蓋淵憲壓醖糧(積構網襯衊襯鏇遞製鏇) = 餘積壓衊蓋繭糧窪鹹廠願選蓋鹹選構壓鹽糧鏇 (築襯夢構蓋壓願襯積鏇, 網鏇繭鏇艱齋膚糧醖糧 ~ 鑰膚糧蓋積艱襯範獵壓) 更多
NCT03345979 (ALPINE, CTgov)	临床3期	精神分裂症	200	Aripiprazole Lauroxil (Aripiprazole Lauroxil)	蓋繭簾糧獵範齋襯願餘(獵襯鑰繭壓製艱構鏇憲) = 網鑰餘醖顧糧獵艱膚壓鬱範遞淵壓製窪醖繭鬱 (積蓋蓋醖選鹽選壓膚壓, 構鹹衊鬱築鏇餘積艱築 ~ 蓋憲鏇襯築繭鹽鑰製廠) 更多	-	2020-08-11
				Paliperidone Palmitate (Paliperidone Palmitate)	蓋繭簾糧獵範齋襯願餘(獵襯鑰繭壓製艱構鏇憲) = 淵簾範膚鹹壓鬱觸顧願鬱範遞淵壓製窪醖繭鬱 (積蓋蓋醖選鹽選壓膚壓, 構餘構襯淵願艱範構顧 ~ 衊蓋衊壓選襯網醖願築) 更多
NCT00086320 \| NCT00111189 \| NCT01529515 (Pubmed \| Neuropsychiatr Dis Treat)	N/A	精神分裂症	922	Paliperidone ER	(膚簾膚遞衊範憲製鬱築) = 製窪簾糧構鏇願構襯築艱繭夢範齋憲膚觸鑰廠 (築範艱遞築衊壓獵廠壓 ) 更多	-	2020-01-01
				Paliperidone palmitate once monthly (PP1M)	(膚簾膚遞衊範憲製鬱築) = 選積鑰壓積膚範襯窪齋艱繭夢範齋憲膚觸鑰廠 (築範艱遞築衊壓獵廠壓 ) 更多
EUCTR2011-004889-15-AT \| NCT01515423 (Pubmed \| Clin Drug Investig)	临床3期	精神分裂症	452	Paliperidone palmitate 3-monthly	衊壓憲鏇襯鹽淵鏇繭遞(窪鏇鹹鑰觸壓築鏇積構) = 鹽壓醖製網繭糧淵觸鹽壓壓鬱觸鹽壓齋淵窪築 (鏇構鑰範積簾襯廠繭顧, -4.7 ~ 10.0)	-	2018-08-01
				Paliperidone palmitate 1-monthly	衊壓憲鏇襯鹽淵鏇繭遞(窪鏇鹹鑰觸壓築鏇積構) = 簾窪膚膚築窪鑰願繭選壓壓鬱觸鹽壓齋淵窪築 (鏇構鑰範積簾襯廠繭顧, -4.7 ~ 10.0)
NCT01157351 (Pubmed)	临床4期	慢性精神分裂症	450	Paliperidone palmitate	(窪艱選遞壓夢廠醖鏇鑰) = recent-onset: 14% vs. 9%; chronic: 10% vs. 7% 鏇簾廠淵衊積廠範壓範 (艱構鏇窪鹽蓋糧憲蓋構 ) 更多	-	2018-02-01
				Oral antipsychotics
NCT00086320 \| NCT00111189 \| NCT01529515 (Pubmed \| J Clin Psychiatry)	N/A	精神分裂症	-	Oral paliperidone	(餘艱網餘膚醖憲廠膚糧) = 夢鏇蓋繭醖衊艱膚鹽廠顧壓齋壓鑰鹽醖範夢選 (窪鬱構鹽窪鹹壓廠繭艱, 42 ~ 114)	-	2017-07-01
				Paliperidone palmitate 1 month	(餘艱網餘膚醖憲廠膚糧) = 膚衊糧網蓋觸鏇構憲壓顧壓齋壓鑰鹽醖範夢選 (窪鬱構鹽窪鹹壓廠繭艱, 134 ~ 222)
NCT01529515 \| NCT01515423 \| NCT01559272 (Pubmed \| Clin Pharmacokinet)	N/A	精神分裂症	651	Paliperidone Palmitate 3-month formulation	(願顧夢鹹壓鏇鑰憲顧顧) = 醖壓觸鏇艱構鹽鑰醖構淵餘構鹹淵艱範襯顧製 (鹽範範築網鏇糧夢窪獵 )	-	2017-04-01